Tier 4 — mechanistic

Sarcopenia: Revised European Consensus on Definition and Diagnosis

Cruz-Jentoft AJ, Bahat G, Bauer J, Boirie Y, Bruyère O, Cederholm T, Cooper C, Landi F, Rolland Y, Sayer AA, Schneider SM, Sieber CC, Topinková E, Vandewoude M, Visser M, Zamboni M
Age and Ageing 2019 48(1):16-31

Bibliography

PubMed
PMID 30312372
PubMed Central
PMC6322506
DOI
10.1093/ageing/afy169
Funding
Not disclosed in the article metadata reviewed
Competing interests
Not disclosed in the article metadata reviewed

Study snapshot

DesignConsensus statement / expert working group definitional update
ModelNot applicable — clinical definitional consensus paper, not an experimental study
SampleNot applicable — expert working-group consensus, not a participant-based intervention.
InterventionNot applicable
DurationNot applicable — clinical consensus and diagnostic guidance.
EndpointsNot applicable — defines diagnostic criteria and cut-off points for sarcopenia

What the study showed, in plain terms

This 2019 European consensus statement updates the clinical definition and diagnostic criteria for sarcopenia, the age-related loss of muscle strength, quantity, and physical performance. It is a definitional and diagnostic framework, not a treatment study, and does not involve fisetin or any other intervention.

Key findings

  • The revised consensus emphasizes low muscle strength as a key indicator of probable sarcopenia.
  • Low muscle quantity or quality confirms sarcopenia; poor physical performance indicates greater severity.
  • This is diagnostic guidance, not a fisetin treatment study.

What this study can and cannot tell us

As a consensus definitional statement rather than a primary study, this paper provides no efficacy or safety data for any intervention, including fisetin.

Citation network

Articles citing this research paper

1 article

Biohack Blueprint analyses that reference this study in their evidence base.

Editorial review

Reviewed by the Biohack Blueprint research team

Last verified

Dr. Khaled Mahmoud, MBBChCritical Care Medicine, Longevity Science & Editorial Direction Dr. Amr Yasser, PhDCardiometabolic, Musculoskeletal, Gut & Bioavailability